lopinavir / ritonavir |
Detailed Prescribing Information |
Lopinavir/ritonavir = Kaletra | |
Dosing Forms |
200 mg lopinavir / 50 mg ritonavir
film coated tablets
approved by
FDA 10.28.2005 100 mg lopinavir / 25 mg ritonavir film coated tablets approved by FDA 11.12.2007 133/33 mg lopinavir/ritonavir soft gel capsules and liquid 400/100 mg per 5 cc - generally not the preferred form |
Dosing |
First Choice: 2 x film-coated 200/50 tablets twice a day with or without food
Without boosting: 3-4 soft gel capsules twice a day with food With boosting: 3 soft gel capsules + 1x100 mg ritonavir, both twice a day with food
|
Mild to moderate hepatic impairment:
increases lopinavir AUC 30% and CMax 20% with a decrease in protein
binding - caution should be exercised Severe hepatic impairment: no data available |
|
Food dependence |
Kaletra soft gel capsules should be taken with food (preferably
a meal) Kaletra film-coated tablets may be taken with or without food. |
Adverse Effects |
Mainly GI disturbance
including nausea, abdominal pain, diarrhea (increased in single daily
dosing)
Also perioral paresthesia, hepatitis, fat redistribution, hyperlipidemia, Type 2 diabetes |
Contraindications | Concomitant use of any of the following: flecainide, propafenone, atemizole, terfenadine, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, midazolam, triazolam, rifampin, St. John’s wort (hypericum perforatum,) lovastatin, simvastatin, fosamprenavir, amprenavir |
Interactions |
Lopinavir/ritonavir produces the following interactions: Increases tenofovir levels significantly (~30%)
in two studies with 1.8% of subjects developing renal insufficiency and 1
patient developed Fanconi syndrome Increases saquinavir (consider 800 mg twice a day of saquinavir) Increases antiarrhythmic levels (use drug level monitoring) Increases clarithromycin levels (decrease clarithromycin for Ccr < 60 cc/hr) Increases ketoconazole, itraconazole levels Increases rifabutin levels (decrease rifabutin to 150 mg every other day and monitor closely for toxicity and consider further dosing reduction) Increases dihydropyridine calcium channel blocker levels Increases intraconazole levels Decreases atovaquone levels Decreases dexamethasone levels Increases sildenafil levels (decrease dose of sildenafil to 25 mg every other day maximum frequency) Decreases methadone levels - withdrawal may be precipitated Decreases oral contraceptive levels (use additional contraceptive method) Variably affects anticoagulation: monitor anticoagulation with warfarin closely |
Lopinavir/ritonavir is affected by the following: Lopinavir levels are decreased very significantly by amprenavir and fosamprenavir Lopinavir levels decreased by nevirapine and efavirenz (increase Kaletra to 4 caps twice a day with food) Delavirdine increases lopinavir levels Fosamprenavir decreases lopinavir levels by 60% and fosamprenavir levels are decreased by up to 70% by lopinavir Anticonvulsants decrease lopinavir levels (avoid use) |
|
No data: lopinavir + atazanavir | |
Suggested laboratory evaluations | Liver profile and glucose monthly x 3 months, then every 3-4 months; lipid profile q3-4 months |
Warnings |
Examine patient's
concomitant medications carefully before prescribing.
See interactions above.
Concomitant fosamprenavir or amprenavir are not
recommended (at least until much more data is available 6/2004) |
Full Prescribing Information | http://www.kaletra.com |
Links to Antiretroviral Sections (click on anything) |
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
efavirenz | nevirapine | delavirdine |
Protease Inhibitors (PI) | Boosted Protease Inhibitors |
saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
Fusion Inhibitors |
enfuvirtide |
Updated 1.11.2008